Landos Biopharma Competitors

Landos Biopharma (NASDAQ:LABP) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.

Profitability

This table compares Landos Biopharma and BioAtla's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Landos Biopharma and BioAtla's top-line revenue, earnings per share and valuation.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Landos Biopharma and BioAtla, as provided by MarketBeat.com.

Landos Biopharma presently has a consensus price target of $25.50, suggesting a potential upside of 126.67%. BioAtla has a consensus price target of $58.00, suggesting a potential upside of 25.98%. Given Landos Biopharma's higher probable upside, research analysts clearly believe Landos Biopharma is more favorable than BioAtla.

Summary

BioAtla beats Landos Biopharma on 2 of the 3 factors compared between the two stocks.

Landos Biopharma (NASDAQ:LABP) and Immunocore (NASDAQ:IMCR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.

Profitability

This table compares Landos Biopharma and Immunocore's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Landos Biopharma and Immunocore's gross revenue, earnings per share and valuation.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Landos Biopharma and Immunocore, as provided by MarketBeat.

Landos Biopharma presently has a consensus price target of $25.50, suggesting a potential upside of 126.67%. Immunocore has a consensus price target of $54.3333, suggesting a potential upside of 37.59%. Given Landos Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Landos Biopharma is more favorable than Immunocore.

Summary

Landos Biopharma beats Immunocore on 3 of the 3 factors compared between the two stocks.

Landos Biopharma (NASDAQ:LABP) and Cullinan Oncology (NASDAQ:CGEM) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.

Profitability

This table compares Landos Biopharma and Cullinan Oncology's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Landos Biopharma and Cullinan Oncology's gross revenue, earnings per share and valuation.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Landos Biopharma and Cullinan Oncology, as provided by MarketBeat.

Landos Biopharma presently has a consensus price target of $25.50, suggesting a potential upside of 126.67%. Cullinan Oncology has a consensus price target of $48.25, suggesting a potential upside of 35.99%. Given Landos Biopharma's higher probable upside, analysts plainly believe Landos Biopharma is more favorable than Cullinan Oncology.

Summary

Landos Biopharma beats Cullinan Oncology on 1 of the 1 factors compared between the two stocks.

Landos Biopharma (NASDAQ:LABP) and Cricut (NASDAQ:EWTX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.

Valuation & Earnings

This table compares Landos Biopharma and Cricut's gross revenue, earnings per share and valuation.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Landos Biopharma and Cricut, as provided by MarketBeat.

Landos Biopharma presently has a consensus price target of $25.50, suggesting a potential upside of 126.67%. Given Landos Biopharma's higher probable upside, analysts plainly believe Landos Biopharma is more favorable than Cricut.

Profitability

This table compares Landos Biopharma and Cricut's net margins, return on equity and return on assets.

Summary

Landos Biopharma beats Cricut on 2 of the 2 factors compared between the two stocks.

Kinnate Biopharma (NASDAQ:KNTE) and Landos Biopharma (NASDAQ:LABP) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.

Earnings and Valuation

This table compares Kinnate Biopharma and Landos Biopharma's gross revenue, earnings per share (EPS) and valuation.

Analyst Ratings

This is a summary of recent ratings for Kinnate Biopharma and Landos Biopharma, as provided by MarketBeat.

Kinnate Biopharma currently has a consensus price target of $52.00, indicating a potential upside of 70.49%. Landos Biopharma has a consensus price target of $25.50, indicating a potential upside of 126.67%. Given Landos Biopharma's higher possible upside, analysts clearly believe Landos Biopharma is more favorable than Kinnate Biopharma.

Profitability

This table compares Kinnate Biopharma and Landos Biopharma's net margins, return on equity and return on assets.

Summary

Kinnate Biopharma beats Landos Biopharma on 2 of the 3 factors compared between the two stocks.

Silverback Therapeutics (NASDAQ:SBTX) and Landos Biopharma (NASDAQ:LABP) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.

Earnings and Valuation

This table compares Silverback Therapeutics and Landos Biopharma's gross revenue, earnings per share (EPS) and valuation.

Analyst Ratings

This is a summary of recent ratings for Silverback Therapeutics and Landos Biopharma, as provided by MarketBeat.

Silverback Therapeutics currently has a consensus price target of $50.25, indicating a potential upside of 32.10%. Landos Biopharma has a consensus price target of $25.50, indicating a potential upside of 126.67%. Given Landos Biopharma's higher possible upside, analysts clearly believe Landos Biopharma is more favorable than Silverback Therapeutics.

Profitability

This table compares Silverback Therapeutics and Landos Biopharma's net margins, return on equity and return on assets.

Summary

Silverback Therapeutics beats Landos Biopharma on 2 of the 3 factors compared between the two stocks.